Alzheimer's disease (FAD) and sporadic, early onset disease: amyloid precursor protein (APP), presenilin 1 (PS-1), and presenilin 2 (PS-2). The relative proportions in which mutations in these genes occur among AD patients in Israel has not been evaluated. To that end, we screened 52 Jewish-Israeli patients with AD: 22 with sporadic, early-onset disease (below 65 years), and 30 with FAD. Mutation screen employed denaturing gradient gel electrophoresis (DGGE) of exon-specific PCRs and restriction enzyme digest. Five patients from three different families displayed mutations within the PS-1 gene: three patients of one family showed a mis-sense mutation in codon 120 (Glu 120Lys), and two other unrelated patients showed an identical mis-sense mutation in codon 318 (Glu318Gly). No patient showed an abnormal migration on DGGE (for APP) or mutant restriction digest pattern (for PS-2) genes. These data may indicate the existence of another familial Alzheimer disease (FAD) gene locus in the Israeli Jewish population.
Introduction
Alzheimer disease (AD), is a neurodegenerative disease affecting up to 15% of the octogenarian population. 1 . The ε4 allele of the APOE gene has been associated with increased AD risk. 2 A subset of AD patients has a family history of the disease, where inheritance follows an autosomal dominant pattern and at times, early age at onset (under 65), with three identified genes involved in familial AD predisposition. A handful of germ line mutations occur within exons 16 and 17 of the amyloid precursor protein (APP) gene on chromosome 21 . [3] [4] [5] [6] Germline mutations in presenilin 1 (PS-1), on chromosome 14 7 presumably account for the majority of familial and early onset AD, 8 with more than 30 different mis-sense mutations reported in ethnically diverse AD families. [8] [9] [10] [11] [12] [13] Finally, in a well defined population of Volga Germans, a single missense mutation (N141I) within presenilin 2 (PS-2) on chromosome 1 accounts for the majority of phenotypically affected individuals. 14, 15 Anecdotal reports of germ line mutation in PS-1 in Jewish FAD patients 9, 16 were reported, but no systematic characterization of germ line mutations in these genes in Jewish FAD patients was published. To that end, we screened 52 Jewish-Israeli patients with either early-onset or FAD for mutations within these genes, using denaturing gradient gel electrophoresis (DGGE), and restriction enzyme digest. In addition, APOE genotype was determined in the same population. (Tables 1a and  Table 1b .)
Materials and Methods

Clinical Characteristics
Fifty-two patients from 49 families formed the basis of this study, which was approved by the Human Ethics Committee. All participants had AD based on standard, accepted criteria. 17, 18 Early-onset and familial AD were diagnosed, if clinical diagnosis of AD with exclusion of other causes of dementia, 19 with onset of symptoms prior to age 65, or at least one additional first degree relative with AD, respectively.
Mutation Analysis and Allelic Determination
DNA extracted from peripheral blood leukocytes using standard protocols, served as a template in the polymerase chain reaction (PCR). The final reaction volume was 50 µl (except for APOE genotyping of 25 µl), containing the standard PCR components. The primers used in DGGE analysis (PS-1 and APP) were based on the melting profiles, 20 predicting that the amplified fragment region of interest would be contained in a single, low-melting domain, increasing the likelihood of mutation detection.
Between 100 and 250 ng of DNA were used per PCR, or in the case of 'nested PCR', 3-5 µl of the 'outer PCR'. Thermal cycling was achieved in a PTC 100-60 thermocycler (M.J. Research, Watertown, MA). An initial 94°C denaturation step for 5' was followed by 30 cycles of denaturation at 94°C (1'), annealing at a temperature of 52-66°C and extending to 72°C (1'), with a final extension step of 5' at 72°C. The cycling profiles and PCR conditions are available. All products (5 µl/reaction), were analysed on a 2% agarose gel.
Of the PCR products of the PS-2 gene or APOE 10 µl were subjected to a Sau3A or HhaI digest respectively (New England Biolabs) at 37°C overnight, and were run on a 2% or 8% polyacrylamide gel respectively, at 250V for 2 hours, and visualized with ethidium bromide.
Parallel denaturing gradient gels were cast and run using the Hoffer Scientific instruments model SE620 (San Francisco, CA) as described. 21 The optimal denaturant range yielding focused bands for the APP and PS-1 genes are summarized in Table 2 .
Of the PCR reaction, 20 µl were loaded onto the gel and, following electrophoresis for 16 hours at 80 volts or 3-4 hours at 160 volts (Table 2) in 60°C on 7% denaturing acrylamide gel, the gels were silver stained. DNA sequencing was performed using a biotinylated primer, as previously described.
22
Results
Patient Characteristics
Fifty-two patients (22 men, 30 women) were analysed. Thirty cases (11 men, 19 women) were designated as familial if there was at least one additional first degree family member with probable AD. Age range at disease onset for these patients was 40-80 years (median 58). The rest (11 men, 11 women) were sporadic, early onset cases (disease onset prior to age 65), and the age range was 42-63 years (median 56), with five patients between 60 and 65 years old. There were 32 patients of Ashkenazi (East European) origin and 20 non-Ashkenazis (Table 1) .
Mutation Analyses and APOE Genotypes
Of 52 patients, 47 did not display any DGGE migration abnormalities in the 10 coding exons PS-1. Three patients from a single Ashkenazi family were found to carry a mis-sense mutation Glu120Lys. 16 Two additional patients, one Ashkenazi and one Moroccan, displayed migration abnormalities in exon 9 in the PS-1 gene (Figure 1a) . Direct DNA sequencing showed a missense mutation: A to G change at codon 318 altering Glutamine to glycine (Figure 1b) .
No patient showed any abnormal migration pattern on DGGE in exons 16 and 17 of the APP gene, whereas a known mutation in exon 16 (K670N/M671L) 23 was easily detected (Figure 2) . Furthermore, no patient displayed the N141I mutation of the PS-2 gene.
APOE genotyping revealed E3 -66.6%, E4 -25% and E2 -8.3% for the familial cases, and E3 -77.2%, E4 -20.4% and E2 -2.2% for the sporadic cases. Notably, two patients were homozygous for the APOE4 allele -one familial case (age at onset 70 years) and a sporadic case (age -53 years).
Case Reports of Patients Displaying PS-1 mutations
The clinical details of the Glu120Gly mutation carriers have been previously reported, 16 and an identical mutation has independently been reported. 10 Two patients carried an identical mutation in codon 318 of the PS-1 gene (Glu318Gly). One is a Jewish-Moroccan male, with slow progressive dementia starting at age 55. Notably, no cases of AD in his family were reported, and his parents died of cancer at 67 (mother) and 72 (father) years of age. The second mutation carrier is a Jewish-Romanian woman, in whom progressive memory impairment started at age 55, with depression being the predominant accompanying manifestation and slow progression of cognitive dysfunction over a 10-year period. The patient's father who died at 84 years suffered from dementia starting at his late seventies.
Discussion
In this study we screened for germ line mutations in three genes known to be associated with AD predisposition in 52 patients with FAD or early-onset AD, representing 49 families, and only five patients from Genetic analysis of familial Alzheimer disease H Reznik-Wolf et althree families were identified as carriers of two distinct mis-sense mutations in PS-1. One mutation, Glu120Lys, was found in a Jewish Ashkenazi family with early onset AD accompanied by seizures. 16 Another mutation, Glu318Gly, was found in two Jewish families from different ethnic backgrounds, Ashkenazi (Romanian) and Moroccan. This mutation was previously reported in one German family. 11 No mutations were found either within exons 16 and 17 of the APP gene, nor was the predominant PS-2 mutation (N141I) detected in any sample.
Low rates of PS-1 mutations were found in Israeli AD patients: for the familial cases mutation rate was 7.4% (2/27) and for the sporadic cases 4.5% (1/22) . In all mutation carriers disease manifestations started before the age of 60 years. This low rate of PS-1 mutation may stem from several causes. First, the phenotypic ascertainment of AD may have been erroneous, since no histopathological proof of the diagnosis is available. However, a unidirectional error in diagnosis of AD by independent experienced physicians, in three medical centres, is highly unlikely. Secondly, the definition of 'familial' AD cases might have been too lax. Given the Jewish Israeli reality of an immigrant population, with truncated families because of the holocaust, and extrapolating from other inherited predispositions, it is acceptable to designate these individuals as FAD.
Lastly, the possibility that existing mutations may have escaped detection seems unlikely given the specificity and sensitivity of DGGE, 21 and its proven ability to identify known and novel mutations in the APP and PS-1 genes. Thus it seems that the paucity of mutations detected in our patients truly reflects a low In summary, the majority of FAD and sporadic, early onset AD cases in Israel do not display mutations within the PS-1, APP or PS-2 genes, despite the adequacy of the mutation detection technique used. This may indicate the existence of other gene loci responsible for AD predisposition in Jewish Israeli families with AD. Moreover, a single mutation, Glu318Gly, seems to occur in ethnically diverse patients, perhaps indicating the significant role that this residue plays in protein function.
